0001209191-22-061408.txt : 20221215
0001209191-22-061408.hdr.sgml : 20221215
20221215160455
ACCESSION NUMBER: 0001209191-22-061408
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221213
FILED AS OF DATE: 20221215
DATE AS OF CHANGE: 20221215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lowrance David L
CENTRAL INDEX KEY: 0001408498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 221464804
MAIL ADDRESS:
STREET 1: 422 WILLIAM WALLACE DRIVE
CITY: FRANKLIN
STATE: TN
ZIP: 37064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6836 BEE CAVE ROAD
STREET 2: BUILDING 3, SUITE 201
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 51285113796
MAIL ADDRESS:
STREET 1: 6836 BEE CAVE ROAD
STREET 2: BUILDING 3, SUITE 201
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-13
0
0001160308
Savara Inc
SVRA
0001408498
Lowrance David L
6836 BEE CAVE ROAD
BUILDING III, SUITE 201
AUSTIN
TX
787846
0
1
0
0
CHIEF FINANCIAL OFFICER
Common Stock
2022-12-13
4
A
0
100000
0.00
A
242793
D
Stock Option (Right to Buy)
1.51
2022-12-13
4
A
0
250000
0.00
A
2032-12-13
Common Stock
250000
250000
D
Represents restricted stock units ("RSUs") that vest in full on December 13, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The option vests and becomes exercisable in sixteen equal installments on each quarterly anniversary of December 13, 2022, subject to the reporting person's continued service with the Issuer.
/s/ David Lowrance
2022-12-15